Endogenous Cannabinoids: Structure and Metabolism

The finding of specific binding sites for Δ9‐tetrahydrocannabinol, the psychoactive component of Cannabis sativa, has led to the discovery of the endocannabinoid system and has emphasised the physiological and pathological relevance of endocannabidoid lipid signalling. Subsequently, an increasing number of papers have been published on the biochemistry and pharmacology of endocannabinoids. An overview of the current understanding of structure and metabolism of the best studied endocannabinoids is provided, with a focus on the mechanisms responsible for their biosynthesis and inactivation.

[1]  R. Palmiter,et al.  Multiple pathways involved in the biosynthesis of anandamide , 2008, Neuropharmacology.

[2]  M. Cascio,et al.  Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation. , 2008, European journal of medicinal chemistry.

[3]  G. I. Kustova,et al.  From the author , 2019, Automatic Documentation and Mathematical Linguistics.

[4]  Marya Liimatta,et al.  Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. , 2007, Biochemistry.

[5]  N. Ueda,et al.  Biosynthetic Pathways of the Endocannabinoid Anandamide , 2007, Chemistry & biodiversity.

[6]  J. Laitinen,et al.  Monoglyceride Lipase as an Enzyme Hydrolyzing 2‐Arachidonoylglycerol , 2007, Chemistry & biodiversity.

[7]  C. Michaux,et al.  Fatty Acid Amide Hydrolase: From Characterization to Therapeutics , 2007, Chemistry & biodiversity.

[8]  J. Wouters,et al.  Disulfiram is an Inhibitor of Human Purified Monoacylglycerol Lipase, the Enzyme Regulating 2‐Arachidonoylglycerol Signaling , 2007, Chembiochem : a European journal of chemical biology.

[9]  S. Petrosino,et al.  Endocannabinoids and the regulation of their levels in health and disease , 2007, Current opinion in lipidology.

[10]  E. Cudaback,et al.  Identification of a Novel Endocannabinoid-Hydrolyzing Enzyme Expressed by Microglial Cells , 2007, The Journal of Neuroscience.

[11]  J. Brioni,et al.  Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets , 2007, Neuropharmacology.

[12]  L. Petrocellis,et al.  Analgesic actions of N‐arachidonoyl‐serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors , 2007, British journal of pharmacology.

[13]  S. Vandevoorde,et al.  Lack of selectivity of URB602 for 2‐oleoylglycerol compared to anandamide hydrolysis in vitro , 2007, British journal of pharmacology.

[14]  N. Ueda,et al.  Discovery and Characterization of a Ca2+-independent Phosphatidylethanolamine N-Acyltransferase Generating the Anandamide Precursor and Its Congeners* , 2006, Journal of Biological Chemistry.

[15]  V. Marzo,et al.  Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. , 2007, Veterinary journal.

[16]  T. Mikkelsen,et al.  A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals* , 2006, Journal of Biological Chemistry.

[17]  B. Cravatt,et al.  Endocannabinoid Biosynthesis Proceeding through Glycerophospho-N-acyl Ethanolamine and a Role for α/β-Hydrolase 4 in This Pathway* , 2006, Journal of Biological Chemistry.

[18]  Bill X. Huang,et al.  A biosynthetic pathway for anandamide , 2006, Proceedings of the National Academy of Sciences.

[19]  H. Tsubokawa,et al.  Forebrain-Specific Inactivation of Gq/G11 Family G Proteins Results in Age-Dependent Epilepsy and Impaired Endocannabinoid Formation , 2006, Molecular and Cellular Biology.

[20]  C. Felder,et al.  Cannabinoids biology: the search for new therapeutic targets. , 2006, Molecular interventions.

[21]  T. Freund,et al.  Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses , 2006, The Journal of Neuroscience.

[22]  Masahiko Watanabe,et al.  Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. , 2006, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  A. Saghatelian,et al.  Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. , 2006, Biochemistry.

[24]  C. Reynet,et al.  Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. , 2006, Cell metabolism.

[25]  T. Bisogno,et al.  Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. , 2006, Biochimica et biophysica acta.

[26]  G. Nomikos,et al.  Identification of a high-affinity binding site involved in the transport of endocannabinoids. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  N. Ueda,et al.  Mammalian cells stably overexpressing N-acylphosphatidylethanolamine-hydrolysing phospholipase D exhibit significantly decreased levels of N-acylphosphatidylethanolamines. , 2005, The Biochemical journal.

[28]  J. Crystal,et al.  An endocannabinoid mechanism for stress-induced analgesia , 2005, Nature.

[29]  B. Cravatt,et al.  Structure and function of fatty acid amide hydrolase. , 2005, Annual review of biochemistry.

[30]  A. Poso,et al.  Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. , 2005, Chemistry & biology.

[31]  K. Waku,et al.  Evidence for the Involvement of the Cannabinoid CB2 Receptor and Its Endogenous Ligand 2-Arachidonoylglycerol in 12-O-Tetradecanoylphorbol-13-acetate-induced Acute Inflammation in Mouse Ear* , 2005, Journal of Biological Chemistry.

[32]  G. Ahern,et al.  Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short‐term food intake in mice via capsaicin receptor TRPV1 , 2005, The Journal of physiology.

[33]  R. Hampson,et al.  Cannabinoid physiology and pharmacology: 30 years of progress , 2004, Neuropharmacology.

[34]  R. Pertwee,et al.  Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2‐arachidonoylglycerol , 2004, British journal of pharmacology.

[35]  D. Piomelli,et al.  RNA Interference Suggests a Primary Role for Monoacylglycerol Lipase in the Degradation of the Endocannabinoid 2-Arachidonoylglycerol , 2004, Molecular Pharmacology.

[36]  M. Fabris,et al.  Stearoylethanolamide exerts anorexic effects in mice via downregulation of liver stearoyl‐coenzyme A desaturase‐1 mRNA expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  T. Freund,et al.  Segregation of two endocannabinoid‐hydrolyzing enzymes into pre‐ and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala , 2004, The European journal of neuroscience.

[38]  M. Murakami,et al.  Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. , 2004, The Biochemical journal.

[39]  D. Fegley,et al.  Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Campbell,et al.  Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. , 2004, Molecular pharmacology.

[41]  N. Ueda,et al.  Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners* , 2004, Journal of Biological Chemistry.

[42]  E. Barker,et al.  Anandamide transport. , 2004, Pharmacology & therapeutics.

[43]  Gareth Williams,et al.  Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain , 2003, The Journal of cell biology.

[44]  V. Di Marzo,et al.  Novel selective and metabolically stable inhibitors of anandamide cellular uptake. , 2003, Biochemical pharmacology.

[45]  J. Ramos,et al.  Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. , 2003, Journal of medicinal chemistry.

[46]  A. Finazzi-Agro’,et al.  Cannabimimetic Activity, Binding, and Degradation of Stearoylethanolamide within the Mouse Central Nervous System , 2002, Molecular and Cellular Neuroscience.

[47]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Pierangelo Geppetti,et al.  An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  F. Bymaster,et al.  Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. , 2002, The Journal of pharmacology and experimental therapeutics.

[50]  S. Gaetani,et al.  An anorexic lipid mediator regulated by feeding , 2001, Nature.

[51]  A. J. Lusis,et al.  Exon-intron organization and chromosomal localization of the mouse monoglyceride lipase gene. , 2001, Gene.

[52]  Z. Vogel,et al.  2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  L. Petrocellis,et al.  N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. , 2000, The Biochemical journal.

[54]  T. Bisogno,et al.  Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity , 2000, FEBS letters.

[55]  L. Petrocellis,et al.  Phosphatidic Acid as the Biosynthetic Precursor of the Endocannabinoid 2‐Arachidonoylglycerol in Intact Mouse Neuroblastoma Cells Stimulated with Ionomycin , 1999, Journal of neurochemistry.

[56]  T. Bisogno,et al.  Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. , 1999, Biochemical and biophysical research communications.

[57]  D. Piomelli,et al.  Functional role of high-affinity anandamide transport, as revealed by selective inhibition. , 1997, Science.

[58]  D. Piomelli,et al.  A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.

[59]  D. Piomelli,et al.  Occurrence and Biosynthesis of Endogenous Cannabinoid Precursor,N-Arachidonoyl Phosphatidylethanolamine, in Rat Brain , 1997, The Journal of Neuroscience.

[60]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[61]  A. Yamashita,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[62]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[63]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[64]  R. Mechoulam,et al.  The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. , 1971, Journal of the American Chemical Society.